Login / Signup

Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy.

Gabriella CapturIvan DoykovSheng-Chia ChungElla FieldAnnabelle BarnesEnpei ZhangImogen HeenanGabrielle NorrishJames C MoonPerry Mark ElliottWendy E HeywoodKevin A MillsJuan Pablo Pablo Kaski
Published in: Circulation. Genomic and precision medicine (2024)
In children, a 7-biomarker proteomics panel can distinguish HCM from controls with high sensitivity and specificity, and a second 4-biomarker panel identifies those at high risk of adverse arrhythmic outcomes, including sudden cardiac death.
Keyphrases
  • hypertrophic cardiomyopathy
  • left ventricular
  • young adults
  • mass spectrometry
  • genome wide
  • heart failure
  • type diabetes
  • metabolic syndrome
  • risk assessment
  • single cell
  • atrial fibrillation
  • insulin resistance
  • label free